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SKELETAL ADAPTATION TO
MECHANICAL STRAIN IN HUMANS
Several lines of clinical evidence (1–3)
suggest that the adult skeleton in humans
continuously responds to change in
mechanical environment to maintain
resultant “elastic” deformation (strain) of
bone; increased or decreased bone strain
would normally induce bone gain or
loss, respectively. Indeed, skeletal adap-
tation to mechanical strain, known as
the mechanostat (4–6), plays a signif-
icant role in the treatment of osteo-
porosis. For example, bone strain from
habitual physical activity decreases when
an osteoporosis drug increases bone
strength, indicating that the effect of osteo-
porosis therapy is limited by mechani-
cal strain-related feedback control; this
mechanostat-based logic is consistent with
various clinical data (3). Approaches to
reduce the limitation of osteoporosis ther-
apy include pharmacologically enhanc-
ing skeletal response to mechanical load-
ing, and earlier experimental studies
using external mechanical loading mod-
els show that intermittent treatment with
parathyroid hormone has such a pos-
sibility (7, 8). Importantly, treatment
with teriparatide could synergistically pro-
duce bone gain with even low, physio-
logical levels of mechanical loading in
humans (9) as well as animals (10).
The present article concisely discusses
the effects of daily or weekly treatment
with teriparatide and proposes a new
mechanostat-based hypothesis for bone
quality associated with mineral versus
collagen.
DAILY OR WEEKLY TREATMENT WITH
TERIPARATIDE IN OSTEOPOROSIS
In Japan, not only daily subcutaneous
injection of teriparatide (20 µg/day) (11–
13) but also weekly subcutaneous injec-
tion of teriparatide (56.5µg/week) (14, 15)
has been approved for the treatment of
adult osteoporosis patients with high risk
of fracture. Interestingly, there are marked
differences in the effects of these two treat-
ments on circulating markers of bone for-
mation and resorption. The daily injection
results in a rapid and sustained increase
in bone formation markers followed by a
delayed increase in bone resorption mark-
ers (12); the period of time during which
the increase in bone formation is superior
to that in bone resorption is called the ana-
bolic window (16). In contrast, the weekly
injection induces only a transient increase
in bone formation markers without an
increase in bone resorption markers (14).
Formation and resorption occur on dif-
ferent surfaces during bone modeling, and
thus modeling-based bone formation and
resorption are not coupled; such uncou-
pling factors include mechanical loading
that stimulates bone formation and sup-
presses bone resorption. Modeling-based
bone formation by histomorphometry (17,
18) as well as an increase in bone formation
markers and a decrease in bone resorp-
tion markers in blood (19) are observed
during the first month of daily treatment
with teriparatide, which is consistent with
clinical finding suggesting that daily treat-
ment with teriparatide and normal phys-
ical activity synergistically produce bone
gain (9). A rapid but transient increase
in bone formation markers without an
increase in bone resorption markers (14)
implies that weekly treatment with teri-
paratide also stimulates modeling-based
bone formation.
On the other hand, long-term daily,
but not weekly, treatment with teriparatide
causes increases in both bone formation
and resorption markers (12, 14). These
systemic changes agree with histomorpho-
metric data showing that 1 or 2 years of
daily treatment with teriparatide results
in an increase in remodeling-based bone
formation (20); resorption followed by
formation occurs on the same surface dur-
ing bone remodeling and thus remodeling-
based bone resorption and formation
are coupled. Increased or decreased bone
remodeling lowers or raises, respectively,
the degree of mineralization (21), and
cortical volumetric bone mineral density
(BMD) is decreased after daily treatment
with teriparatide (13). In contrast, weekly
treatment with teriparatide is unlikely to
increase bone remodeling because neither
an increase in bone resorption markers nor
a decrease in cortical volumetric BMD is
not found (14, 15).
PERSPECTIVES ON THE EFFECTS OF
TERIPARATIDE ON BONE FRAGILITY
An important goal of osteoporosis ther-
apy is to prevent hip fracture associated
with significant morbidity and mortal-
ity. The latest systematic review suggests
that bone fragility at the hip is improved
by daily treatment with teriparatide (22);
the effect of weekly treatment with teri-
paratide on non-vertebral fracture risk
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FIGURE 1 | Force displacement curve of a bone. (A)Treatment with an
ideal osteoporosis drug improves bone fragility by increasing both of the
force and displacement at failure (23). X denotes fracture. (B)The curve
would consist of the pre-yield “elastic” deformation associated with
mineral and the post-yield “plastic” deformation associated with collagen.
Consequently, mechanical strain-related feedback control, the
mechanostat, could work against mineral-related, but not collagen-related,
impairment of bone quality. X denotes fracture. (C)The pre-yield “elastic”
deformation can be modified by osteoporosis therapy that (i) directly
enhances the response to mechanical loading and increases the slope of
the curve (upper) or (ii) lowers mineral-related bone quality and results in
compensatory bone gain by the mechanostat to maintain the slope of the
curve (lower). Note that, in the latter case, the yield force can be
increased if compensated efficiently.
is under investigation. Here, we present
mechanostat-based perspectives on this
topic.
Fall-related fracture occurs if the energy
from the fall is higher than that the
bone can absorb. Force displacement curve
obtained from a biomechanical test, in
which a bone is loaded until it fractures,
shows that work to failure (energy absorp-
tion), the area under the curve, represents
bone fragility, and an ideal strategy for the
improvement of bone fragility is to increase
both the force and displacement at failure
(23) (Figure 1A).
From a material point of view, stiff-
ness and toughness of bone tissue gen-
erally depend on mineral and collagen,
respectively (24). There is a yield force
at which a bone begins to deform plas-
tically, and mechanical strain from nor-
mal physical activity would be linked to
the pre-yield “elastic” deformation associ-
ated with mineral but not to the post-yield
“plastic”deformation associated with colla-
gen (Figure 1B). Consequently, mechanical
strain-related feedback control could com-
pensate mineral-related, but not collagen-
related, impairment of bone quality to
maintain “elastic” deformation. Indeed,
this theory is compatible with clinical
data relating to bone quality. Examples
of the mechanostat-based compensation
for mineral-related impairment of bone
quality would include rickets/osteomalacia
and use of warfarin (3, 25–27), while
the impairment of bone quality associated
with collagen cross-links significantly con-
tributes to skeletal fragility in diabetes
(28–30).
It is possible to speculate that treatment
with teriparatide improves bone fragility
at the hip through the mechanostat-
based “modeling-related direct” and
“remodeling-related compensatory”mech-
anisms (Figure 1C). Both daily and weekly
treatments are expected to have the for-
mer effect by the enhancement of skeletal
response to mechanical loading (7–10).
In contrast, the latter effect is linked to
daily treatment; a decrease in the degree of
mineralization after daily but not weekly
treatment (13, 15) might act to improve
bone fragility if compensated efficiently,
because compensatory bone gain by the
mechanostat to maintain the pre-yield
“elastic” deformation could increase the
yield force at which a bone begins to
deform plastically and thus the energy
that the bone can absorb. This possibility
is supported by histomorphometric data
showing that one or two years of the treat-
ment results in increases in modeling- and
remodeling-based bone formation (20),
because the mechanosat suggests that the
former “modeling-related direct” effect
does not continue for a long time (3).
Finally, the mechanostat-based theory
appears to be inconsistent with clinical
data that daily or weekly treatment with
teriparatide stimulates bone accrual at the
endosteal rather than periosteal surface,
because the strain level would be lower
at the former site; endosteal as well as
trabecular, but not periosteal, bone appo-
sition is detected by computed tomogra-
phy after daily (13) and weekly (15) treat-
ments. Teriparatide-induced bone model-
ing is dose-dependent (17, 18), implying
higher concentrations of the agent at the
trabecular and endosteal surfaces. Regard-
less of the mechanism, the mechanostat
suggests that inner bone gain could limit
outer bone gain, because bone gain in the
inner compartments is likely to decrease
bone strain in the outer compartment.
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